Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice

Anne Granger, Ibrahim Abdullah, Faith Huebner, Andrea Stout, Tao Wang, Thomas Huebner, Jonathan A. Epstein, Peter J. Gruber

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Limitation of infarct size is a major goal of therapy for acute coronary syndromes, and research has focused on achieving rapid patency of infarct-related vessels. However, new understandings of epigenetic modifications during ischemia suggest additional targeted approaches that have not been extensively explored. Here, we show that ischemia induces histone deacetylase (HDAC) activity in the heart with deacetylation of histones H3/4 in vitro and in vivo. We show, utilizing a standard murine model of ischemia-reperfusion, that chemical HDAC inhibitors significantly reduce infarct area, even when delivered 1 h after the ischemic insult. We demonstrate that HDAC inhibitors prevent ischemia-induced activation of gene programs that include hypoxia inducible factor-1α, cell death, and vascular permeability in vivo and in vitro, thus providing potential mechanisms to explain reduced vascular leak and myocardial injury. In vitro, siRNA knockdown experiments implicate HDAC4 as a mediator of the effects in ischemic cardiac myocytes. These results demonstrate that HDAC inhibitors alter the response to ischemic injury in the heart and reduce infarct size, suggesting novel therapeutic approaches for acute coronary syndromes.

Original languageEnglish (US)
Pages (from-to)3549-3560
Number of pages12
JournalFASEB Journal
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2008

Fingerprint

Myocardial Reperfusion Injury
Histone Deacetylase Inhibitors
Histone Deacetylases
Reperfusion Injury
Myocardial Ischemia
Ischemia
Acute Coronary Syndrome
Hypoxia-Inducible Factor 1
Cell death
Heart Injuries
Histones
Small Interfering RNA
Capillary Permeability
Genes
Chemical activation
Cardiac Myocytes
Epigenomics
Transcriptional Activation
Reperfusion
Blood Vessels

Keywords

  • Cardiomyocytes
  • Heart
  • Hypoxia inducible factor 1

ASJC Scopus subject areas

  • Biotechnology
  • Biochemistry
  • Molecular Biology
  • Genetics

Cite this

Granger, A., Abdullah, I., Huebner, F., Stout, A., Wang, T., Huebner, T., ... Gruber, P. J. (2008). Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB Journal, 22(10), 3549-3560. https://doi.org/10.1096/fj.08-108548

Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. / Granger, Anne; Abdullah, Ibrahim; Huebner, Faith; Stout, Andrea; Wang, Tao; Huebner, Thomas; Epstein, Jonathan A.; Gruber, Peter J.

In: FASEB Journal, Vol. 22, No. 10, 01.10.2008, p. 3549-3560.

Research output: Contribution to journalArticle

Granger, A, Abdullah, I, Huebner, F, Stout, A, Wang, T, Huebner, T, Epstein, JA & Gruber, PJ 2008, 'Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice', FASEB Journal, vol. 22, no. 10, pp. 3549-3560. https://doi.org/10.1096/fj.08-108548
Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB Journal. 2008 Oct 1;22(10):3549-3560. https://doi.org/10.1096/fj.08-108548
Granger, Anne ; Abdullah, Ibrahim ; Huebner, Faith ; Stout, Andrea ; Wang, Tao ; Huebner, Thomas ; Epstein, Jonathan A. ; Gruber, Peter J. / Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. In: FASEB Journal. 2008 ; Vol. 22, No. 10. pp. 3549-3560.
@article{cd760f41c2a14b05ba66ac8172877720,
title = "Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice",
abstract = "Limitation of infarct size is a major goal of therapy for acute coronary syndromes, and research has focused on achieving rapid patency of infarct-related vessels. However, new understandings of epigenetic modifications during ischemia suggest additional targeted approaches that have not been extensively explored. Here, we show that ischemia induces histone deacetylase (HDAC) activity in the heart with deacetylation of histones H3/4 in vitro and in vivo. We show, utilizing a standard murine model of ischemia-reperfusion, that chemical HDAC inhibitors significantly reduce infarct area, even when delivered 1 h after the ischemic insult. We demonstrate that HDAC inhibitors prevent ischemia-induced activation of gene programs that include hypoxia inducible factor-1α, cell death, and vascular permeability in vivo and in vitro, thus providing potential mechanisms to explain reduced vascular leak and myocardial injury. In vitro, siRNA knockdown experiments implicate HDAC4 as a mediator of the effects in ischemic cardiac myocytes. These results demonstrate that HDAC inhibitors alter the response to ischemic injury in the heart and reduce infarct size, suggesting novel therapeutic approaches for acute coronary syndromes.",
keywords = "Cardiomyocytes, Heart, Hypoxia inducible factor 1",
author = "Anne Granger and Ibrahim Abdullah and Faith Huebner and Andrea Stout and Tao Wang and Thomas Huebner and Epstein, {Jonathan A.} and Gruber, {Peter J.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1096/fj.08-108548",
language = "English (US)",
volume = "22",
pages = "3549--3560",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "10",

}

TY - JOUR

T1 - Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice

AU - Granger, Anne

AU - Abdullah, Ibrahim

AU - Huebner, Faith

AU - Stout, Andrea

AU - Wang, Tao

AU - Huebner, Thomas

AU - Epstein, Jonathan A.

AU - Gruber, Peter J.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Limitation of infarct size is a major goal of therapy for acute coronary syndromes, and research has focused on achieving rapid patency of infarct-related vessels. However, new understandings of epigenetic modifications during ischemia suggest additional targeted approaches that have not been extensively explored. Here, we show that ischemia induces histone deacetylase (HDAC) activity in the heart with deacetylation of histones H3/4 in vitro and in vivo. We show, utilizing a standard murine model of ischemia-reperfusion, that chemical HDAC inhibitors significantly reduce infarct area, even when delivered 1 h after the ischemic insult. We demonstrate that HDAC inhibitors prevent ischemia-induced activation of gene programs that include hypoxia inducible factor-1α, cell death, and vascular permeability in vivo and in vitro, thus providing potential mechanisms to explain reduced vascular leak and myocardial injury. In vitro, siRNA knockdown experiments implicate HDAC4 as a mediator of the effects in ischemic cardiac myocytes. These results demonstrate that HDAC inhibitors alter the response to ischemic injury in the heart and reduce infarct size, suggesting novel therapeutic approaches for acute coronary syndromes.

AB - Limitation of infarct size is a major goal of therapy for acute coronary syndromes, and research has focused on achieving rapid patency of infarct-related vessels. However, new understandings of epigenetic modifications during ischemia suggest additional targeted approaches that have not been extensively explored. Here, we show that ischemia induces histone deacetylase (HDAC) activity in the heart with deacetylation of histones H3/4 in vitro and in vivo. We show, utilizing a standard murine model of ischemia-reperfusion, that chemical HDAC inhibitors significantly reduce infarct area, even when delivered 1 h after the ischemic insult. We demonstrate that HDAC inhibitors prevent ischemia-induced activation of gene programs that include hypoxia inducible factor-1α, cell death, and vascular permeability in vivo and in vitro, thus providing potential mechanisms to explain reduced vascular leak and myocardial injury. In vitro, siRNA knockdown experiments implicate HDAC4 as a mediator of the effects in ischemic cardiac myocytes. These results demonstrate that HDAC inhibitors alter the response to ischemic injury in the heart and reduce infarct size, suggesting novel therapeutic approaches for acute coronary syndromes.

KW - Cardiomyocytes

KW - Heart

KW - Hypoxia inducible factor 1

UR - http://www.scopus.com/inward/record.url?scp=54049090410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049090410&partnerID=8YFLogxK

U2 - 10.1096/fj.08-108548

DO - 10.1096/fj.08-108548

M3 - Article

C2 - 18606865

AN - SCOPUS:54049090410

VL - 22

SP - 3549

EP - 3560

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 10

ER -